The STRASS trial: an important step in the right direction
Mené sur 266 patients atteints d'un sarcome rétropéritonéal primitif (âge : 18 ans ou plus ; durée médiane de suivi : 43,1 mois), cet essai international de phase III évalue l'intérêt, du point de vue de la survie sans récidive abdominale et des effets indésirables, d'une radiothérapie pré-opératoire
As clinicians, our practice patterns are formed from a mixture of evidence-based medicine, clinical experience, and, at times, a fair amount of dogma. This reality of clinical medicine is even more so for clinicians who treat rare cancers, such as soft tissue sarcoma, in which the underlying complexity and diversity of the disease has limited the development of robust disease site-specific or histotype-specific evidence to guide clinical management.
The Lancet Oncology , commentaire, 2019